Traws Pharma, Inc.
TRAW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.7% | 100% | 100% | 100% |
| R&D Expenses | $130 | $11 | $11 | $7 |
| G&A Expenses | $12 | $9 | $8 | $9 |
| SG&A Expenses | $12 | $9 | $8 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$93 | $0 | $0 | $0 |
| Operating Expenses | $50 | $21 | $20 | $17 |
| Operating Income | -$49 | -$20 | -$20 | -$16 |
| % Margin | -21,835.4% | -8,981.4% | -8,684.5% | -7,299.1% |
| Other Income/Exp. Net | -$117 | $1 | $1 | $0 |
| Pre-Tax Income | -$167 | -$19 | -$19 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55 | -$19 | -$19 | -$16 |
| % Margin | -24,192% | -8,384.1% | -8,391.2% | -7,151.8% |
| EPS | -35.21 | -22.569 | -22.675 | -24.006 |
| % Growth | -56% | 0.5% | 5.5% | – |
| EPS Diluted | -35.21 | -22.569 | -22.675 | -24.006 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$167 | -$20 | -$20 | -$16 |
| % Margin | -73,677.4% | -8,974.3% | -8,678.3% | -7,292.9% |